Literature DB >> 20463037

Autoimmune diseases prior to the diagnosis of multiple sclerosis: a population-based case-control study.

A Langer-Gould1, K B Albers, S K Van Den Eeden, L M Nelson.   

Abstract

The objective of this study was to determine whether patients with multiple sclerosis (MS) are more likely to have other autoimmune disorders particularly prior to the diagnosis of MS. We conducted a population-based case-control study of patients enrolled in the Northern California Kaiser Permanente Medical Care Program. Electronic clinical records through 2005 were used to ascertain incident and prevalent MS cases and identify the presence and timing of 44 other diagnoses. Controls were matched 5:1 for gender, age, and Kaiser membership characteristics. We identified 5296 MS cases (including 924 diagnosed between 2001 and 2004) and 26,478 matched controls. Prior to MS diagnosis, cases were more likely than controls to have uveitis (OR = 3.2, 95%; CI 1.7-5.7), inflammatory bowel disease (IBD, OR = 1.7; 95%CI 1.2-2.5), and Bell's palsy (OR = 3.2; 95%CI 1.2-8.3). Cases were also more likely to develop Guillain- Barré syndrome (GBS, OR = 5.0; 95%CI 1.6-15.4) and bullous pemphigoid (OR = 6.7; 95%CI 1.5-29.9). Cases were not more likely than controls to have or to develop rheumatoid arthritis, lupus or thyroiditis. MS may share environmental triggers, genetic susceptibilities and/or alterations in immune homeostasis with IBD and uveitis, but not with other autoimmune disorders.

Entities:  

Mesh:

Year:  2010        PMID: 20463037     DOI: 10.1177/1352458510369146

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  40 in total

1.  A Monocentric Retrospective Observational Study of Comorbidities in Patients Affected by Autoimmune Bullous Diseases.

Authors:  Martina Ferranti; Giulia Gobbo; Giulia Tadiotto Cicogna; Mauro Alaibac
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

Review 2.  [Neuroimmunology and rheumatology: overlap and differential diagnoses].

Authors:  C Trebst; T Kümpfel
Journal:  Nervenarzt       Date:  2018-10       Impact factor: 1.214

3.  Multiple sclerosis: autoimmune associations in multiple sclerosis.

Authors:  Cris S Constantinescu; Bruno Gran
Journal:  Nat Rev Neurol       Date:  2010-11       Impact factor: 42.937

Review 4.  Vaccines in Multiple Sclerosis.

Authors:  Eric M L Williamson; Salim Chahin; Joseph R Berger
Journal:  Curr Neurol Neurosci Rep       Date:  2016-04       Impact factor: 5.081

Review 5.  Multiple sclerosis and inflammatory bowel diseases: a systematic review and meta-analysis.

Authors:  Maria Kosmidou; Aristeidis H Katsanos; Konstantinos H Katsanos; Athanassios P Kyritsis; Georgios Tsivgoulis; Dimitrios Christodoulou; Sotirios Giannopoulos
Journal:  J Neurol       Date:  2016-11-22       Impact factor: 4.849

Review 6.  Cutting-edge issues in autoimmune uveitis.

Authors:  Roger A Levy; Francisco Assis de Andrade; Ivan Foeldvari
Journal:  Clin Rev Allergy Immunol       Date:  2011-10       Impact factor: 8.667

7.  Comorbidities at multiple sclerosis diagnosis.

Authors:  Agnès Fromont; Christine Binquet; Fabien Rollot; Romain Despalins; Alain Weill; Laurence Clerc; Claire Bonithon-Kopp; Thibault Moreau
Journal:  J Neurol       Date:  2013-08-02       Impact factor: 4.849

Review 8.  Autoimmune disease in people with multiple sclerosis and their relatives: a systematic review and meta-analysis.

Authors:  Ruth Dobson; Gavin Giovannoni
Journal:  J Neurol       Date:  2013-01-12       Impact factor: 4.849

9.  Looks can be deceiving: three cases of neurological diseases mimicking Guillain-Barrè syndrome.

Authors:  G Sciacca; A Nicoletti; S Lo Fermo; G Mostile; C Giliberto; Mario Zappia
Journal:  Neurol Sci       Date:  2015-12-26       Impact factor: 3.307

10.  Early predictors of Guillain-Barré syndrome in the life course of women.

Authors:  Nathalie Auger; Caroline Quach; Jessica Healy-Profitós; Trish Dinh; Michaël Chassé
Journal:  Int J Epidemiol       Date:  2018-02-01       Impact factor: 7.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.